They manifested as bradycardia or bronchospasm (38% patients), combination of bradycardia and vascular hypotension or bronchospasm (18%), or combination of 3-4 types of adverse reactions (26%); in the first and second comparison groups – in 36% and 30%, respectively (

<0.05).

The most severe multifactorial adverse reactions developed…[Read more]